celecoxib has been researched along with Metastase in 52 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preclinical results showing therapeutic effect and low toxicity of metronomic chemotherapy with cyclophosphamide (Cy) + celecoxib (Cel) for mammary tumors encouraged its translation to the clinic for treating advanced breast cancer patients (ABCP)." | 9.22 | Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response. ( Alasino, CM; Mainetti, LE; Perroud, HA; Pezzotto, SM; Queralt, F; Rico, MJ; Rozados, VR; Scharovsky, OG, 2016) |
| "Irinotecan-based chemotherapy regimens are 1 option for treatment of metastatic colorectal cancer (mCRC)." | 9.14 | Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. ( Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X, 2009) |
| "The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma." | 9.12 | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. ( Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006) |
| " To explore the possibility that COX-2 is a therapeutic target, we conducted a phase II study of celecoxib, a selective COX-2 inhibitor, and trastuzumab in patients with HER-2/neu-overexpressing metastatic breast cancer that had progressed while receiving trastuzumab." | 9.11 | Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. ( D'Andrea, GM; Dang, CT; Dannenberg, AJ; Dickler, MN; Hudis, CA; Moasser, MM; Norton, L; Panageas, KS; Seidman, AD; Subbaramaiah, K; Theodoulou, M, 2004) |
| "Celecoxib use during chemotherapy adversely affected survival in patients with breast cancer, and the effect was more marked in PTGS2-low and/or estrogen receptor-negative tumors." | 7.91 | Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. ( Aouchiche, B; Asselain, B; Benchimol, G; Brain, E; Edelman, M; Espié, M; Gao, J; Giacchetti, S; Hamy, AS; Laas, E; Laé, M; Marty, M; Pierga, JY; Pistilli, B; Reyal, F; Tury, S; Wang, X, 2019) |
| " Dacarbazine (DTIC) is one of the most commonly used drugs in the treatment of metastatic melanoma." | 7.83 | In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine. ( Averineni, RK; Guan, X; Sadhu, SS; Seefeldt, T; Wang, S; Yang, Y, 2016) |
| "Celecoxib significantly inhibits invasion of Ewing sarcoma cells in vitro." | 7.78 | Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. ( Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM, 2012) |
| "The therapeutic benefits of combined MCT with cyclophosphamide plus celecoxib on mammary adenocarcinomas together with its very low toxicity profile warrant further study in an attempt to make the translation into the clinic." | 7.77 | Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. ( Bonfil, RD; Mainetti, LE; Rossa, A; Rozados, VR; Scharovsky, OG, 2011) |
| " The present study was designed to evaluate the inhibitory effects of the COX-2 inhibitor celecoxib on the growth of colorectal cancer liver metastases in a syngeneic rat model, CC531." | 7.74 | Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. ( de Boeck, G; de Bruijn, EA; de Heer, P; Guertens, G; Junggeburt, JM; Koudijs, MM; Kuppen, PJ; Nagelkerke, JF; Sandel, MH; van de Velde, CJ, 2008) |
| " This prompted us to investigate the chemopreventive potential of celecoxib, a selective COX-2 inhibitor, against prostate carcinogenesis in a transgenic adenocarcinoma of the mouse prostate (TRAMP) model." | 7.72 | Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. ( Adhami, VM; Fu, P; Gupta, S; Hafeli, UO; Lewin, JS; MacLennan, GT; Mukhtar, H; Subbarayan, M, 2004) |
| "Celecoxib is a selective inhibitor of COX-2, whose connection with the development and progression of human tumors has been extensively studied." | 5.40 | Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. ( Gan, L; Hu, GQ; Hu, GY; Jiang, JZ; Li, WW; Liu, DB; Long, GX; Mei, Q; Sun, W; Wang, JF, 2014) |
| "Preclinical results showing therapeutic effect and low toxicity of metronomic chemotherapy with cyclophosphamide (Cy) + celecoxib (Cel) for mammary tumors encouraged its translation to the clinic for treating advanced breast cancer patients (ABCP)." | 5.22 | Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response. ( Alasino, CM; Mainetti, LE; Perroud, HA; Pezzotto, SM; Queralt, F; Rico, MJ; Rozados, VR; Scharovsky, OG, 2016) |
| "Irinotecan-based chemotherapy regimens are 1 option for treatment of metastatic colorectal cancer (mCRC)." | 5.14 | Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. ( Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X, 2009) |
| "The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma." | 5.12 | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. ( Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006) |
| " To explore the possibility that COX-2 is a therapeutic target, we conducted a phase II study of celecoxib, a selective COX-2 inhibitor, and trastuzumab in patients with HER-2/neu-overexpressing metastatic breast cancer that had progressed while receiving trastuzumab." | 5.11 | Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. ( D'Andrea, GM; Dang, CT; Dannenberg, AJ; Dickler, MN; Hudis, CA; Moasser, MM; Norton, L; Panageas, KS; Seidman, AD; Subbaramaiah, K; Theodoulou, M, 2004) |
| "Celecoxib use during chemotherapy adversely affected survival in patients with breast cancer, and the effect was more marked in PTGS2-low and/or estrogen receptor-negative tumors." | 3.91 | Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. ( Aouchiche, B; Asselain, B; Benchimol, G; Brain, E; Edelman, M; Espié, M; Gao, J; Giacchetti, S; Hamy, AS; Laas, E; Laé, M; Marty, M; Pierga, JY; Pistilli, B; Reyal, F; Tury, S; Wang, X, 2019) |
| " Dacarbazine (DTIC) is one of the most commonly used drugs in the treatment of metastatic melanoma." | 3.83 | In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine. ( Averineni, RK; Guan, X; Sadhu, SS; Seefeldt, T; Wang, S; Yang, Y, 2016) |
| "Celecoxib significantly inhibits invasion of Ewing sarcoma cells in vitro." | 3.78 | Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. ( Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM, 2012) |
| "The therapeutic benefits of combined MCT with cyclophosphamide plus celecoxib on mammary adenocarcinomas together with its very low toxicity profile warrant further study in an attempt to make the translation into the clinic." | 3.77 | Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. ( Bonfil, RD; Mainetti, LE; Rossa, A; Rozados, VR; Scharovsky, OG, 2011) |
| "Celecoxib prevents lung metastasis in a murine model of Ewing sarcoma with no effect on tumor size or neovascularization." | 3.77 | Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. ( Edelman, M; Gendy, AS; Glick, RD; Lipskar, A; Soffer, SZ; Steinberg, BM, 2011) |
| "Morphine and its congener opioids are the main therapy for severe pain in cancer." | 3.74 | COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. ( Farooqui, M; Griffin, RJ; Gupta, K; Li, Y; Poonawala, T; Rogers, T; Song, CW, 2007) |
| " The present study was designed to evaluate the inhibitory effects of the COX-2 inhibitor celecoxib on the growth of colorectal cancer liver metastases in a syngeneic rat model, CC531." | 3.74 | Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. ( de Boeck, G; de Bruijn, EA; de Heer, P; Guertens, G; Junggeburt, JM; Koudijs, MM; Kuppen, PJ; Nagelkerke, JF; Sandel, MH; van de Velde, CJ, 2008) |
| "Celecoxib significantly reduced establishment of metastases by circulating tumor cells in a murine model." | 3.73 | Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer. ( Backhus, LM; Bart, RD; Bremner, RM; Castanos, R; Lin, GY; Sievers, E; Starnes, VA, 2006) |
| " This prompted us to investigate the chemopreventive potential of celecoxib, a selective COX-2 inhibitor, against prostate carcinogenesis in a transgenic adenocarcinoma of the mouse prostate (TRAMP) model." | 3.72 | Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. ( Adhami, VM; Fu, P; Gupta, S; Hafeli, UO; Lewin, JS; MacLennan, GT; Mukhtar, H; Subbarayan, M, 2004) |
| "Celecoxib combined with chemotherapy offers more clinical benefits for COX-2 positive advanced gastric cancer patients." | 2.90 | A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study. ( Chen, Z; Guan, Q; Guo, Q; Li, Q; Liu, M; Wang, J; Wang, Y; Ye, Y; Zhou, Y, 2019) |
| "The GC cells from the resected gastric cancer specimens were isolated by immunomagnetic separation." | 2.72 | [The inhibitive effects of celecoxib combined with octreotide on the metastasis of human gastric cancer in vivo]. ( Chen, ZX; Huang, MH; Huang, MT; Tang, CW; Wang, CH; Wei, B; Zhang, B, 2006) |
| "Celecoxib was administered orally at 400 mg twice a day starting 2 days after the first dose of gemcitabine." | 2.71 | A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. ( Abbruzzese, JL; Du, M; Lenzi, R; Plunkett, W; Wolff, R; Xiong, HQ, 2005) |
| " Epidemiologic data showed that chronic intake of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) could reduce the incidence of colorectal cancer." | 2.42 | Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. ( Chen, BD; Chou, TH; Chu, AJ, 2004) |
| "The fifth case was a breast cancer patient with distant metastases in CR, while receiving beta-interferon and interleukin-2 in addition to conventional hormone therapy." | 1.51 | Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports. ( Carpi, A; Ferrari, P; Morganti, R; Nicolini, A, 2019) |
| "The progression and metastasis of pancreatic ductal adenocarcinoma (PDAC) is highly dependent on the tumour microenvironment." | 1.51 | Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. ( Bai, X; Chen, Q; Chen, Y; Dang, X; Fu, Q; Liang, T; Lou, Y; Wang, J; Wei, T; Yang, J; Ye, M; Zhang, J; Zhang, Q; Zhang, X, 2019) |
| "The anti-pancreatic cancer activities of celecoxib (0, 20, 60 and 100 μmol/L) were investigated by cell viability and migration of Panc-1 and Bxpc-3 cells in vitro." | 1.48 | Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities. ( Hong, Y; Liu, N; Liu, Z; Ma, M; Qiu, X; Sheng, X; Tang, B; Xiong, S; Yang, D; Zhou, K; Zuo, C, 2018) |
| "FLP inhibited tumor growth and metastasis in a Lewis lung xenograft mice model through the Cox-2 pathway." | 1.42 | Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model. ( Bao, Y; Gao, Y; Guo, Q; He, S; Hirasaki, Y; Hou, W; Hua, B; Li, C; Li, W; Liu, R; Pei, Y; Qi, X; Zhang, Y; Zheng, H, 2015) |
| "We recently demonstrated that both murine and human carcinomas grow significantly slower in mice on low carbohydrate (CHO), high protein diets than on isocaloric Western diets and that a further reduction in tumor growth rates occur when the low CHO diets are combined with the cyclooxygenase-2 inhibitor, celecoxib." | 1.40 | A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis. ( Adomat, HH; Bennewith, KL; Dang, NH; Guns, ES; Hamilton, MJ; Ho, VW; Hsu, BE; Krystal, G; Samudio, I; Weljie, A, 2014) |
| "Celecoxib is a selective inhibitor of COX-2, whose connection with the development and progression of human tumors has been extensively studied." | 1.40 | Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. ( Gan, L; Hu, GQ; Hu, GY; Jiang, JZ; Li, WW; Liu, DB; Long, GX; Mei, Q; Sun, W; Wang, JF, 2014) |
| "A549 metastases were increased in mice after exogenous PGE2 injection." | 1.40 | Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated β-catenin pathway. ( Da, L; Feng, D; Jiang, F; Li, M; Xu, L; Yang, X; Yin, R; Zhang, S; Zhang, Z, 2014) |
| "Human hepatoma cell lines were treated with lipopolysaccharide (LPS) or cyclooxygenase-2 inhibitor, Celecoxib, and in vitro proliferation, apoptosis, and cell cycle progression were assessed." | 1.39 | Proinflammatory conditions promote hepatocellular carcinoma onset and progression via activation of Wnt and EGFR signaling pathways. ( Bai, L; Mao, ZY; Su, D; Wang, LJ; Zhang, T, 2013) |
| "The sites of secondary metastasis and the associated inflammatory microenvironment were evaluated." | 1.37 | Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. ( Ghosh, S; Gruber, HE; Mukherjee, P; Pathangey, LB; Roy, LD; Tinder, TL, 2011) |
| "We report a three-fold increase in lung metastasis and a significant increase in the incidence of bone metastasis in the pro-arthritic and arthritic mice compared to non-arthritic control mice." | 1.35 | Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. ( Das Roy, L; Gruber, HE; Mukherjee, P; Pathangey, LB; Schettini, JL; Tinder, TL, 2009) |
| "Tumor invasion into adjacent organs and metastasis were not observed in the DMAPT/celecoxib treatment groups." | 1.35 | Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. ( Crooks, PA; Holcomb, B; Neelakantan, S; Njoku, V; Ralstin, M; Schmidt, CM; Sweeney, CJ; Wu, H; Yip-Schneider, MT, 2008) |
| "Pancreatic neoplasms are associated with a poor prognosis, regardless of treatment modality." | 1.33 | Resection and use of a cyclooxygenase-2 inhibitor for treatment of pancreatic adenocarcinoma in a cockatiel. ( Bartick, T; Chen, S, 2006) |
| "We used pairs of head and neck squamous cell carcinoma (HNSCC) cell lines derived from primary and metastatic tumors of the same patient to analyze eicosanoid metabolites by ESI-LC/MS/MS and COX/LOX expression by western immunoblotting." | 1.32 | Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. ( Lotan, R; Newman, RA; Schroeder, CP; Yang, P, 2004) |
| "However, it is still unknown whether pancreatic cancer might also be influenced." | 1.31 | Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters. ( Bisevac, M; Guski, H; Khodadayan, C; Kilian, M; Müller, JM; Schimke, I; von Seebach, M; Wenger, FA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (40.38) | 29.6817 |
| 2010's | 30 (57.69) | 24.3611 |
| 2020's | 1 (1.92) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, T | 2 |
| Liu, H | 1 |
| Li, Y | 3 |
| Li, C | 4 |
| Wan, G | 1 |
| Chen, B | 1 |
| Wang, Y | 3 |
| Chen, Q | 1 |
| Wang, J | 2 |
| Zhang, Q | 2 |
| Zhang, J | 2 |
| Lou, Y | 1 |
| Yang, J | 2 |
| Chen, Y | 2 |
| Wei, T | 1 |
| Fu, Q | 1 |
| Ye, M | 1 |
| Zhang, X | 2 |
| Dang, X | 1 |
| Liang, T | 1 |
| Bai, X | 1 |
| Nicolini, A | 1 |
| Ferrari, P | 1 |
| Morganti, R | 1 |
| Carpi, A | 1 |
| Mao, L | 1 |
| Yue, J | 1 |
| Zhou, H | 1 |
| Fan, D | 1 |
| Buraschi, S | 1 |
| Iozzo, RV | 1 |
| Bi, X | 1 |
| Ko, CJ | 1 |
| Lan, SW | 1 |
| Lu, YC | 1 |
| Cheng, TS | 1 |
| Lai, PF | 1 |
| Tsai, CH | 1 |
| Hsu, TW | 1 |
| Lin, HY | 1 |
| Shyu, HY | 1 |
| Wu, SR | 1 |
| Lin, HH | 1 |
| Hsiao, PW | 1 |
| Chen, CH | 1 |
| Huang, HP | 1 |
| Lee, MS | 1 |
| Zhou, P | 1 |
| Qin, J | 1 |
| Li, G | 1 |
| Zhang, N | 1 |
| Chen, P | 1 |
| Zuo, C | 1 |
| Hong, Y | 1 |
| Qiu, X | 1 |
| Yang, D | 1 |
| Liu, N | 1 |
| Sheng, X | 1 |
| Zhou, K | 1 |
| Tang, B | 1 |
| Xiong, S | 1 |
| Ma, M | 1 |
| Liu, Z | 1 |
| Sun, Y | 1 |
| Li, X | 1 |
| Zhang, L | 2 |
| Liu, X | 1 |
| Jiang, B | 1 |
| Long, Z | 1 |
| Jiang, Y | 1 |
| Hamy, AS | 1 |
| Tury, S | 1 |
| Wang, X | 1 |
| Gao, J | 1 |
| Pierga, JY | 2 |
| Giacchetti, S | 1 |
| Brain, E | 2 |
| Pistilli, B | 1 |
| Marty, M | 2 |
| Espié, M | 1 |
| Benchimol, G | 1 |
| Laas, E | 1 |
| Laé, M | 1 |
| Asselain, B | 1 |
| Aouchiche, B | 1 |
| Edelman, M | 3 |
| Reyal, F | 1 |
| Guo, Q | 2 |
| Li, Q | 1 |
| Liu, M | 1 |
| Chen, Z | 1 |
| Ye, Y | 1 |
| Guan, Q | 1 |
| Zhou, Y | 1 |
| Patil, V | 1 |
| Noronha, V | 1 |
| Krishna, V | 1 |
| Joshi, A | 1 |
| Prabhash, K | 1 |
| Wang, LJ | 1 |
| Bai, L | 1 |
| Su, D | 1 |
| Mao, ZY | 1 |
| Zhang, S | 1 |
| Da, L | 1 |
| Yang, X | 1 |
| Feng, D | 1 |
| Yin, R | 1 |
| Li, M | 1 |
| Zhang, Z | 1 |
| Jiang, F | 1 |
| Xu, L | 1 |
| Li, WW | 1 |
| Long, GX | 1 |
| Liu, DB | 1 |
| Mei, Q | 1 |
| Wang, JF | 1 |
| Hu, GY | 1 |
| Jiang, JZ | 1 |
| Sun, W | 1 |
| Gan, L | 1 |
| Hu, GQ | 1 |
| Ho, VW | 1 |
| Hamilton, MJ | 1 |
| Dang, NH | 1 |
| Hsu, BE | 1 |
| Adomat, HH | 1 |
| Guns, ES | 1 |
| Weljie, A | 1 |
| Samudio, I | 1 |
| Bennewith, KL | 1 |
| Krystal, G | 1 |
| Lönnroth, C | 1 |
| Andersson, M | 1 |
| Asting, AG | 1 |
| Nordgren, S | 1 |
| Lundholm, K | 1 |
| Liu, R | 1 |
| Zheng, H | 1 |
| Li, W | 1 |
| He, S | 1 |
| Hirasaki, Y | 1 |
| Hou, W | 1 |
| Hua, B | 1 |
| Bao, Y | 1 |
| Gao, Y | 1 |
| Qi, X | 1 |
| Pei, Y | 1 |
| Zhang, Y | 1 |
| Perroud, HA | 2 |
| Alasino, CM | 1 |
| Rico, MJ | 2 |
| Mainetti, LE | 3 |
| Queralt, F | 1 |
| Pezzotto, SM | 1 |
| Rozados, VR | 3 |
| Scharovsky, OG | 3 |
| Sadhu, SS | 1 |
| Wang, S | 1 |
| Averineni, RK | 1 |
| Seefeldt, T | 1 |
| Yang, Y | 1 |
| Guan, X | 1 |
| James, ND | 2 |
| Sydes, MR | 2 |
| Clarke, NW | 2 |
| Mason, MD | 2 |
| Dearnaley, DP | 2 |
| Anderson, J | 2 |
| Popert, RJ | 2 |
| Sanders, K | 2 |
| Morgan, RC | 2 |
| Stansfeld, J | 2 |
| Dwyer, J | 2 |
| Masters, J | 2 |
| Parmar, MK | 2 |
| Yip-Schneider, MT | 1 |
| Wu, H | 1 |
| Njoku, V | 1 |
| Ralstin, M | 1 |
| Holcomb, B | 1 |
| Crooks, PA | 1 |
| Neelakantan, S | 1 |
| Sweeney, CJ | 1 |
| Schmidt, CM | 1 |
| Jackson, NA | 1 |
| Barrueco, J | 1 |
| Soufi-Mahjoubi, R | 1 |
| Marshall, J | 1 |
| Mitchell, E | 1 |
| Meyerhardt, J | 1 |
| Das Roy, L | 1 |
| Pathangey, LB | 2 |
| Tinder, TL | 2 |
| Schettini, JL | 1 |
| Gruber, HE | 2 |
| Mukherjee, P | 2 |
| Bidard, FC | 1 |
| Mathiot, C | 1 |
| Delaloge, S | 1 |
| Giachetti, S | 1 |
| de Cremoux, P | 1 |
| Bhatt, RS | 1 |
| Merchan, J | 1 |
| Parker, R | 1 |
| Wu, HK | 1 |
| Seery, V | 1 |
| Heymach, JV | 1 |
| Atkins, MB | 1 |
| McDermott, D | 1 |
| Sukhatme, VP | 1 |
| Rossa, A | 2 |
| Bonfil, RD | 1 |
| Singh, B | 1 |
| Cook, KR | 1 |
| Vincent, L | 1 |
| Hall, CS | 1 |
| Martin, C | 1 |
| Lucci, A | 1 |
| Luo, WR | 1 |
| Li, LX | 1 |
| Li, SY | 1 |
| Jiang, HG | 1 |
| Chen, XY | 1 |
| Chan, E | 1 |
| Lafleur, B | 1 |
| Rothenberg, ML | 1 |
| Merchant, N | 1 |
| Lockhart, AC | 1 |
| Trivedi, B | 1 |
| Chung, CH | 1 |
| Coffey, RJ | 1 |
| Berlin, JD | 1 |
| Gendy, AS | 1 |
| Lipskar, A | 1 |
| Glick, RD | 2 |
| Steinberg, BM | 2 |
| Soffer, SZ | 2 |
| Gravitz, L | 1 |
| Roy, LD | 1 |
| Ghosh, S | 1 |
| Matar, P | 1 |
| Zacarías Fluck, MF | 1 |
| Fernández Zenóbi, MV | 1 |
| Roggero, EA | 1 |
| Gervasoni, SI | 1 |
| Sánchez, AM | 1 |
| Celoria, GC | 1 |
| Font, MT | 1 |
| Barlow, M | 1 |
| Wenger, FA | 1 |
| Kilian, M | 1 |
| Bisevac, M | 1 |
| Khodadayan, C | 1 |
| von Seebach, M | 1 |
| Schimke, I | 1 |
| Guski, H | 1 |
| Müller, JM | 1 |
| Roh, JL | 1 |
| Sung, MW | 1 |
| Park, SW | 1 |
| Heo, DS | 1 |
| Lee, DW | 1 |
| Kim, KH | 1 |
| Gupta, S | 1 |
| Adhami, VM | 1 |
| Subbarayan, M | 1 |
| MacLennan, GT | 1 |
| Lewin, JS | 1 |
| Hafeli, UO | 1 |
| Fu, P | 1 |
| Mukhtar, H | 1 |
| Dang, CT | 1 |
| Dannenberg, AJ | 1 |
| Subbaramaiah, K | 1 |
| Dickler, MN | 1 |
| Moasser, MM | 1 |
| Seidman, AD | 1 |
| D'Andrea, GM | 1 |
| Theodoulou, M | 1 |
| Panageas, KS | 1 |
| Norton, L | 1 |
| Hudis, CA | 1 |
| Schroeder, CP | 1 |
| Yang, P | 1 |
| Newman, RA | 1 |
| Lotan, R | 1 |
| Chu, AJ | 1 |
| Chou, TH | 1 |
| Chen, BD | 1 |
| Xiong, HQ | 1 |
| Plunkett, W | 1 |
| Wolff, R | 1 |
| Du, M | 1 |
| Lenzi, R | 1 |
| Abbruzzese, JL | 1 |
| Wirth, LJ | 1 |
| Haddad, RI | 1 |
| Lindeman, NI | 1 |
| Zhao, X | 1 |
| Lee, JC | 1 |
| Joshi, VA | 1 |
| Norris, CM | 1 |
| Posner, MR | 1 |
| Chen, S | 1 |
| Bartick, T | 1 |
| Grösch, S | 1 |
| Maier, TJ | 1 |
| Schiffmann, S | 1 |
| Geisslinger, G | 1 |
| Backhus, LM | 1 |
| Sievers, E | 1 |
| Lin, GY | 1 |
| Castanos, R | 1 |
| Bart, RD | 1 |
| Starnes, VA | 1 |
| Bremner, RM | 1 |
| Gogas, H | 1 |
| Polyzos, A | 1 |
| Stavrinidis, I | 1 |
| Frangia, K | 1 |
| Tsoutsos, D | 1 |
| Panagiotou, P | 1 |
| Markopoulos, C | 1 |
| Papadopoulos, O | 1 |
| Pectasides, D | 1 |
| Mantzourani, M | 1 |
| Middleton, M | 1 |
| Vaiopoulos, G | 1 |
| Fountzilas, G | 1 |
| Wilson, KS | 1 |
| Huang, MT | 1 |
| Chen, ZX | 1 |
| Wei, B | 1 |
| Zhang, B | 1 |
| Wang, CH | 1 |
| Huang, MH | 1 |
| Tang, CW | 1 |
| Farooqui, M | 1 |
| Rogers, T | 1 |
| Poonawala, T | 1 |
| Griffin, RJ | 1 |
| Song, CW | 1 |
| Gupta, K | 1 |
| de Heer, P | 1 |
| Sandel, MH | 1 |
| Guertens, G | 1 |
| de Boeck, G | 1 |
| Koudijs, MM | 1 |
| Nagelkerke, JF | 1 |
| Junggeburt, JM | 1 |
| de Bruijn, EA | 1 |
| van de Velde, CJ | 1 |
| Kuppen, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer[NCT01041781] | Phase 3 | 313 participants (Actual) | Interventional | 2010-02-28 | Terminated (stopped due to DSMB recommendation) | ||
| STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476] | Phase 2/Phase 3 | 11,992 participants (Actual) | Interventional | 2005-07-08 | Active, not recruiting | ||
| IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence[NCT01204242] | Phase 2 | 78 participants (Actual) | Interventional | 2009-08-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment (NCT01041781)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 61.04 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 55.06 |
Overall survival time is defined as the time from randomization to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Time between randomization and death from any cause, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 11.4 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 12.5 |
Prognostic value of urinary prostaglandin metabolites (PGE-M) levels for worse PFS for patients who had baseline urinary PGE-M above/below the first quartile (Q1, 10.09). Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| PGE-M < Q1 | 7.7 |
| PGE-M >= Q1 | 4.9 |
prognostic value of urinary prostaglandin metabolites (PGE-M) levels for worse PFS for patients who had baseline urinary PGE-M above/below the median quartile (Q2, 15.38). Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| PGE-M < Q2 | 6.2 |
| PGE-M >= Q2 | 4.2 |
Prognostic value of urinary prostaglandin metabolites (PGE-M) levels for worse PFS for patients who had baseline urinary PGE-M above/below the median quartile (Q3, 27.86). Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| PGE-M < Q3 | 6.0 |
| PGE-M >= Q3 | 3.0 |
Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Time between randomization and disease relapse or death from any cause, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 5.16 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 5.26 |
The response rate (percentage) is the percent of patients whose best response was Complete Response (CR) or Partial Response (PR) as defined by RECIST 1.1 criteria. Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients. Response rates (including complete and partial response) will be tested using Fisher's exact test (NCT01041781)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 40 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 35 |
3 reviews available for celecoxib and Metastase
| Article | Year |
|---|---|
Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; | 2016 |
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinogens | 2004 |
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anti-Inflammatory Agents, N | 2006 |
12 trials available for celecoxib and Metastase
| Article | Year |
|---|---|
A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Capecitabine; Celecoxib; Chemotherapy, Adjuvant; Dis | 2019 |
Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2016 |
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphospho | 2009 |
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cytokines; Drug Administrati | 2010 |
Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2011 |
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breas | 2004 |
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administ | 2005 |
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2005 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhi | 2006 |
[The inhibitive effects of celecoxib combined with octreotide on the metastasis of human gastric cancer in vivo].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female; Humans; Male; Matrix Metal | 2006 |
37 other studies available for celecoxib and Metastase
| Article | Year |
|---|---|
A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
Topics: Alginates; Animals; Antineoplastic Agents; Benzoic Acid; Breast Neoplasms; Celecoxib; Cell Adhesion; | 2019 |
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celecoxib; Ce | 2019 |
Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.
Topics: Adult; Aged; alpha-Tocopherol; Antineoplastic Agents; Breast Neoplasms; Celecoxib; Colonic Neoplasms | 2019 |
Decorin deficiency promotes epithelial-mesenchymal transition and colon cancer metastasis.
Topics: Animals; Azoxymethane; beta Catenin; Cadherins; Cancer-Associated Fibroblasts; Celecoxib; Colitis-As | 2021 |
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
Topics: Animals; Celecoxib; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; HEK2 | 2017 |
Combination therapy of PKCζ and COX-2 inhibitors synergistically suppress melanoma metastasis.
Topics: Amidines; Animals; Benzene Derivatives; Cdh1 Proteins; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 | 2017 |
Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities.
Topics: CD56 Antigen; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Down-Reg | 2018 |
Cell Permeable NBD Peptide-Modified Liposomes by Hyaluronic Acid Coating for the Synergistic Targeted Therapy of Metastatic Inflammatory Breast Cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Movem | 2019 |
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Celecoxi | 2019 |
Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2013 |
Proinflammatory conditions promote hepatocellular carcinoma onset and progression via activation of Wnt and EGFR signaling pathways.
Topics: Animals; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Proliferation; Disease Progres | 2013 |
Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated β-catenin pathway.
Topics: Animals; Antigens, CD; beta Catenin; Cadherins; Celecoxib; Cell Line, Tumor; Cell Proliferation; Din | 2014 |
Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity.
Topics: Carcinoma; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coloring Agents; Cyclooxy | 2014 |
A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis.
Topics: Animals; Celecoxib; Diet Therapy; Diet, Carbohydrate-Restricted; Dietary Proteins; Disease Models, A | 2014 |
Preoperative low dose NSAID treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Tumor; Celecoxib; Colorectal Neoplasms; Female; | 2014 |
Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model.
Topics: Animals; Carcinoma, Lewis Lung; Celecoxib; Cyclooxygenase 2; Drugs, Chinese Herbal; Heterografts; In | 2015 |
In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
Topics: Animals; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dacarbazine; Disease Models, An | 2016 |
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Proliferation; Chemokines, | 2008 |
Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis; Autoimmune Dise | 2009 |
Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclophosphamide | 2011 |
Role of COX-2 in tumorospheres derived from a breast cancer cell line.
Topics: Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase | 2011 |
[Influence of celecoxib on invasiveness of human high-metastatic nasopharyngeal carcinoma cell line CNE-2Z].
Topics: Apoptosis; Cadherins; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Gen | 2010 |
Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 In | 2011 |
Chemoprevention: First line of defence.
Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I | 2011 |
Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Bone Neoplasms; Celecoxib; Collagen Type | 2011 |
[Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Celecoxib; Cl | 2012 |
Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma.
Topics: Basement Membrane; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2; Cyc | 2012 |
Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cricetinae; Hydroxyurea; Lipid Peroxida | 2002 |
Celecoxib can prevent tumor growth and distant metastasis in postoperative setting.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cell Division; Cell Line, Tumor | 2004 |
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Biomarkers, Tumor; Celecoxib; Cell Division; Cyclo | 2004 |
Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Dose-Response Re | 2004 |
Resection and use of a cyclooxygenase-2 inhibitor for treatment of pancreatic adenocarcinoma in a cockatiel.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Bird Diseases; Celecoxib; Cockatoos; Cyclooxygenas | 2006 |
Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer.
Topics: Adenocarcinoma; Animals; Blotting, Western; Celecoxib; Cell Adhesion; Cyclooxygenase 2 Inhibitors; D | 2006 |
Cyclooxygenase-2 inhibition and regression of metastatic melanoma.
Topics: Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Progression; Female; Gene | 2006 |
COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia.
Topics: Analgesia; Analgesics, Opioid; Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; C | 2007 |
Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Celecoxib; Cell Survival; Colo | 2008 |